We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Telaprevir Gets Priority Review, Begins Phase III Trials
Telaprevir Gets Priority Review, Begins Phase III Trials
February 2, 2011
The FDA has granted priority review to Vertex’s telaprevir, an oral protease inhibitor to treat hepatitis C (HCV), tightening its race with Merck’s boceprevir, which received priority review earlier in January.